Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
House dust mite sublingual immunotherapy in children with allergic rhinitis
NL-OMON28314Recruiting
- Sponsor
- Artu Biologicals
- Start
- Sep 2005
- Modality
- Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Randomised, double-blind trial of house dust mite allergen in allergic rhinitis (AR) (2 arms), sponsored by Artu Biologicals. Primary endpoint: Mean rhinitis symptom score. Started Sep 2005; status: recruiting.
02
Drugs
house dust mite allergen
03
Conditions
allergic rhinitis (AR)
Beyond the preview
Go deeper on NL-OMON28314.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON28314.